iBio Appoints James Abbey, Ph.D. as Vice President of Strategic Business Development
October 02 2017 - 8:30AM
iBio, Inc. (NYSE AMERICAN:IBIO), a leading provider of plant-based
biotechnology for developing and manufacturing biological products,
announced today the appointment of James Abbey, Ph.D. as Vice
President of Strategic Business Development. Dr.
Abbey’s background includes in-depth experience and leadership of
strategic partnership and growth opportunities for major medical
research and development institutions.
Prior to joining iBio, Dr. Abbey served as the
Director for Global and Corporate Partnerships for the Texas
A&M University System, where he established and managed key
collaborations with major global organizations across industry and
academia, drawing in more than $100 million in research funding to
support the University System’s research initiatives. He also
previously served as the International Strategic Collaborations
Adviser and Director for the Texas/UK Collaborative &
International Collaboration at Swansea University in Wales, United
Kingdom. In that role, he helped establish Europe’s first Center
for NanoHealth and led the creation of the Texas/UK Research
Collaborative & International Collaboration, which brings
together leading medical research institutions from the United
Kingdom and Texas to harness their collective experience and
excellence for the sake of continued innovation and
development.
“We are very pleased to have James join the iBio
team at this time,” commented B. Kay, CEO and Executive Chairman.
“He has a proven track record of successfully executing domestic
and international strategic business development collaborations.
Adding James’ capabilities to our recently-achieved capacity for
multiple, concurrent product development projects at cGMP quality
is expected to accelerate growth of our CDMO business.”
Dr. Abbey holds a Ph.D. in Nanotechnology from
Swansea University in Wales United Kingdom, a M.B.A. from the
University of Wales, United Kingdom, and a B.S. from the University
of North Texas. He also holds research affiliations with
Houston Methodist Hospital Research Institute as Assistant
Affiliate Member and is an Adjunct Professor in the College of
Veterinary Medicine at Texas A&M University.
About iBio, Inc.
iBio, a leader in developing plant-based
biopharmaceuticals, provides a range of product and process
development, analytical, and manufacturing services at the
large-scale development and manufacturing facility of its
subsidiary iBio CDMO LLC in Bryan, Texas. The facility houses
laboratory and pilot-scale operations, as well as large-scale
automated hydroponic systems capable of growing over four million
plants as "in process inventory" and delivering over 300 kilograms
of therapeutic protein pharmaceutical active ingredient per year.
iBio applies its technology for the benefit of its clients and the
advancement of its own product interests. The Company’s pipeline is
comprised of proprietary candidates for the treatment of a range of
fibrotic diseases including idiopathic pulmonary fibrosis, systemic
sclerosis, and scleroderma. IBIO-CFB03, based on the Company's
proprietary gene expression technology, is the Company’s lead
therapeutic candidate being advanced for IND development.
FORWARD-LOOKING STATEMENTS
STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED
TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE
MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.
SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS
COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND
THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY
ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE, AND
DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS
THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN
THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION.
ICR, Inc. (Investor and Media Inquiries):
Stephanie Carrington Tel. +1 646-277-1282
stephanie.carrington@icrinc.com
James HeinsTel. +1
203-682-8251James.Heins@icrinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024